

## DRAWINGS OF SPECIFICATION

---




**FIG. 1**




**FIG. 2**




**FIG. 3**




**FIG. 4**




**FIG. 5**




**FIG. 6**




**FIG. 7**




**FIG. 8**




**FIG. 9**




**FIG. 10**





**FIG. 11**



● VP101  
■ BsAbB7  
▲ BsAbB8  
◆ Bevacizumab


VP101  
 $R^2 = 1.000$   
EC50 = 0.130

BsAbB7  
 $R^2 = 1.000$   
EC50 = 0.171

BsAbB8  
 $R^2 = 1.000$   
EC50 = 0.159

Bevacizumab  
 $R^2 = 0.999$   
EC50 = 0.092

FIG. 12



● VP101  
▲ Nivolumab  
○ 14C12 H1L1

FIG. 13





**FIG. 14**




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31